Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: venlafaxine hydrochloride

« Back to Dashboard

Venlafaxine hydrochloride is the generic ingredient in three branded drugs marketed by Wyeth Pharms Inc, Anchen Pharms, Aurobindo Pharma Ltd, Dr Reddys Labs Ltd, Mylan, Orchid Hlthcare, Teva, Torrent Pharms Llc, Valeant Bermuda, Wockhardt, Zydus Pharms Usa Inc, Osmotica Pharm, Sun Pharma Global, Alembic Pharms Ltd, Amneal Pharms, Aurobindo Pharma, Heritage Pharms Inc, Pliva Hrvatska Doo, Sandoz, Sun Pharm Inds Inc, Vintage, and Zydus Pharms Usa, and is included in twenty-six NDAs. There are seven patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

There are sixty-four drug master file entries for venlafaxine hydrochloride. Eighteen suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for Generic Name: venlafaxine hydrochloride

Drug Master File Entries: see list64
Suppliers: see list18
Therapeutic Class:Antidepressants

Pharmacology for Ingredient: venlafaxine hydrochloride


Applicant Application No. Form Dosage
<disabled><disabled>CAPSULE, EXTENDED RELEASE; ORAL150MG
<disabled><disabled>CAPSULE, EXTENDED RELEASE; ORAL37.5MG

Clinical Trials for: venlafaxine hydrochloride

Co-Administration of LDX (SPD489) and Venlafaxine XR (EFFEXOR XR) in Healthy Volunteers
Status: Completed Condition: Healthy

Venlafaxine Hydrochloride 150 mg Extended-Release Capsules Under Fed Conditions
Status: Completed Condition: Healthy

Venlafaxine Hydrochloride 150 mg Extended-Release Capsules Sprinkle Study
Status: Completed Condition: Healthy

Study to Examine the Effect of Gastric Bypass Surgery on Venlafaxine ER Blood Levels
Status: Recruiting Condition: Bariatric Surgery; Gastric Bypass; Roux-en-Y Gastric Bypass

Venlafaxine Hydrochloride 150 mg Extended-Release Capsules Under Fasting Conditions
Status: Completed Condition: Healthy

Repetitive Transcranial Magnetic Stimulation Compared or Associated With Venlafaxine for Depressive Disorder
Status: Recruiting Condition: Depression

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Dr Reddys Labs Ltd
venlafaxine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL078421May 6, 2011RXNo<disabled><disabled>
Alembic Pharms Ltd
venlafaxine hydrochloride
TABLET;ORAL078932Dec 14, 2010RXNo<disabled><disabled>
Amneal Pharms
venlafaxine hydrochloride
TABLET;ORAL079098May 11, 2010RXNo<disabled><disabled>
Pliva Hrvatska Doo
venlafaxine hydrochloride
TABLET;ORAL078517Jun 13, 2008DISCNNo<disabled><disabled>
Wyeth Pharms Inc
venlafaxine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL020699Oct 20, 1997RXNo6,444,708*PED<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology